25 completed, 12 recruiting, 10 active not recruiting, 7 terminated. 64 Phase 2, 15 Phase 1, 7 Phase 3.
Follow Systemic Vasculitis: new trials by email Literature Review of Systemic Vasculitis trials Research Report on Systemic Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of VIS954 in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis VIS954, Standard Of Care (SOC), Placebo - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 2 | Not yet recruiting | Otsuka Pharmaceutical Development & Commercialization, Inc. | 75 | 2026-12-15 | 2026-10-29 |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Obinutuzumab Beta Combined With Low-dose Glucocorticoid in New-onset ANCA-Associated Glomerulonephritis Obinutuzumab beta, Glucocorticoids - ANCA-Associated Glomerulonephritis (AAGN), ANCA-Associated Vasculitis (AAV) | Phase 2 | Recruiting | Chinese PLA General Hospital | 20 | 2026-08-21 | 2026-09-15 |
| Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV) NM8074, Placebo - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Not yet recruiting | NovelMed Therapeutics | 12 | 2026-06-01 | 2025-03-11 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Avacopan, Placebo - Granulomatosis With Polyangiitis, Wegener's | Phase 2 / Phase 3 | Recruiting | Robert Spiera, MD | 30 | 2026-05-22 | 2026-09-02 |
| CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis CC-97540, Lymphodepletion Chemotherapy - Antineutrophil Cytoplasmic Antibody-associated Vasculitis | Phase 1 / Phase 2 | Active not recruiting | Marcela V. Maus, M.D.,Ph.D. | 12 | 2026-03-30 | 2026-09-10 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis Obinutuzumab - Granulomatosis With Polyangiitis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 33 | 2025-12-19 | 2026-03-06 |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Placebo, Tarperprumig - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Phase 2 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 78 | 2025-11-26 | 2026-11-02 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA Rapcabtagene autoleucel, Active Comparator, Glucocorticoids - ANCA Associated Vasculitis (AAV) | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 126 | 2025-03-13 | 2026-09-04 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | Nkarta, Inc. | 240 | 2024-11-04 | 2026-10-30 |
| The Efficacy and Safety of Treatment with Telitacicept in Antineutrophil Cytoplasmic Antibody-associated Nephritis (AAGN) Telitacicept 160mg, Prednisone (and methylprednisolone), Cyclophosphamide - Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN) | Phase 1 / Phase 2 | Active not recruiting | Renmin Hospital of Wuhan University | 15 | 2024-10-10 | 2024-10-24 |
| Iptacopan in Patients With ANCA Associated Vasculitis Iptacopan, Placebo, Rituximab - Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 84 | 2024-08-05 | 2026-10-15 |
| Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) CD19- BCMA CAR-T cells - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 75 | 2024-07-10 | 2024-10-15 |
| Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis Tezepelumab, Placebo - EGPA - Eosinophilic Granulomatosis With Polyangiitis | Phase 2 | Active not recruiting | Imperial College London | 42 | 2024-05-15 | 2026-04-29 |
Showing 20 of 64. Sign in to see all of them.
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (32) · Granulomatosis with Polyangiitis (30) · Vasculitis (20) · Microscopic Polyangiitis (16) · Churg-Strauss Syndrome (11) · Lupus Erythematosus, Systemic (8) · Scleroderma, Systemic (8) · Myositis (6) · Arthritis, Rheumatoid (5) · Dermatomyositis (4) · Polyarteritis Nodosa (4) · Sjogren's Syndrome (4) · Giant Cell Arteritis (3) · Glomerulonephritis (3)
Cardiovascular Diseases (63) · Skin Diseases (63) · Skin and Connective Tissue Diseases (63) · Vascular Diseases (63) · Immune System Diseases (62) · Skin Diseases, Vascular (62) · Autoimmune Diseases (60) · Vasculitis (44) · Lung Diseases (31) · Respiratory Tract Diseases (31) · Lung Diseases, Interstitial (30) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (27) · Nervous System Diseases (25) · Brain Diseases (18)
Rituximab (12) · Cyclophosphamide (10) · Prednisone (8) · Glucocorticoids (5) · Azathioprine (4) · Mycophenolic Acid (4) · mepolizumab (4) · Abatacept (3) · Etanercept (3) · Infliximab (3) · Methotrexate (3) · Methylprednisolone (3) · Plasma Exchange (2) · Pneumococcal Vaccines (2) · Prednisolone (2)
National Institute of Allergy and Infectious Diseases (NIAID) (6) · Assistance Publique - Hôpitaux de Paris (5) · Cambridge University Hospitals NHS Foundation Trust (5) · University of Pennsylvania (3) · Imperial College London (2) · InflaRx GmbH (2) · Novartis Pharmaceuticals (2) · Peking University Third Hospital (2) · University of North Carolina, Chapel Hill (2) · Alexion Pharmaceuticals, Inc. (1) · Alpine Immune Sciences, Inc. (1) · Amgen (1) · Anthera Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Cartesian Therapeutics (1)
United States (30) · United Kingdom (17) · France (10) · China (9) · Canada (8) · Germany (7) · Italy (6) · Spain (4) · Australia (3) · Czechia (3) · Netherlands (3) · Turkey (Türkiye) (3) · Argentina (2) · Belgium (2) · Brazil (2)
David Jayne (3) · Peter A. Merkel, MD, MPH (3) · John H. Stone, MD, MPH (2) · Patrick H Nachman, MD (2) · Ulrich Specks, MD (2) · Alan Salama (1) · Anja Pfaff, PhD (1) · Carlo Buzio, MD (1) · Carol A. Langford, MD, MHS (1) · Caroline OS Savage (1) · Fernando C. Fervenza, M.D., Ph.D. (1)
PMID 33164993, PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 19451574, PMID 20647199, PMID 21325353, PMID 22127969, PMID 22975753, PMID 23615499, PMID 23754238, PMID 23902481, PMID 24323392, PMID 25047592, PMID 25776953, PMID 26312852, PMID 26387933, PMID 26621483, PMID 27450392, PMID 27696762, PMID 28592297, PMID 29016646, PMID 30102389, PMID 30472651, PMID 31216123, PMID 32990324, PMID 33128347, PMID 34164952, PMID 34618687, PMID 35279811, PMID 36906660, PMID 40632630
2025 (2), P01DK058335 (2), 2016 (1), 2017 (1), 2023 (1), U54AR057319 (1), UL1RR024150 (1)